Back
February 26, 2021
February 26, 2021
2 min. read

The Latest in Ophthalmology News: February 26, 2021

Medly

This week, we’re sharing the most recent top stories in opthamology news. This month many new medications became available in the OTC market with Alcon releasing allergy drops, Pataday and Allergan releasing antihistamine drops, Alaway.

Additionally, a large case study showed outcomes of same-day vs. delayed surgery with multifocal IOLs, showed that changes in best corrected visual acuity was comparable, and so were complication rates, with high patient satisfaction in both groups.

partner banner

Read more on these stories below:

Allergy itch relief drop now available over the counter Ophthalmology Times, February 18, 2021

The drop, formerly prescribed as Pazeo, joins Alcon’s over-the-counter ocular allergy portfolio to meet a variety of patient needs.

Study shows comparable outcomes of same-day vs. delayed surgery with multifocal IOLs Healio, February 23, 2021

A new study finds, immediate sequential bilateral cataract surgery with implantation of multifocal IOLs showed comparable outcomes to delayed sequential bilateral cataract surgery in a large case series.

Allergan Submits New Drug Application for Investigational Eye Drop for the Treatment of Presbyopia Eyewire, February 25, 2021

Allergan announced that it has submitted a new drug application to the FDA for investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia. The FDA is expected to act on the NDA by the end of 2021.

Bausch + Lomb Launches Alaway Preservative Free Antihistamine Eye Drops Eyewire, February 23, 2021

Bausch + Lomb announced the US launch of Alaway Preservative Free (ketotifen fumarate ophthalmic solution 0.035%) antihistamine eye drops. Bausch + Lomb says Alaway is the first and only over-the-counter (OTC) preservative-free antihistamine eye itch relief drop approved by the FDA.

Researchers: Recall Contaminated Acetazolamide Shots

Researchers at the University of Kentucky have called on the FDA to recall certain formulations of the injectable diuretic acetazolamide after their own chemical analysis turned up unknown impurities; it is not clear what those contaminants are, as the researchers couldn't find matches in pharmacology libraries.

Want to keep updated with Medly? Subscribe to our monthly newsletter!

UTM Source:UTM Campaign:UTM Content:UTM Medium:UTM Term:UTM Device:Landing Page:Company:Last Name:
Join Medly
Partner with Medly
Live Chat